Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

• Status: Completed
• Trial end date: 2016-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Frederick Schmitt; University of Kentucky
• Collaborators: National Cancer Institute (NCI); National Institute on Aging (NIA)
• Treatments: alpha-Tocopherol; Selenium; Tocopherols; Tocotrienols; Vitamin E; Vitamins

Criteria

Inclusion Criteria:

• Participating in SELECT Prevention study;

• 62 years or older if other ethnic origin, or 60 years or older if African-American or Hispanic;

• General good health with no neurological or psychiatric illness.

Exclusion Criteria:

The SELECT doctors or staff will review the PREADVISE applicants' medical history and drugs to verify that they have no condition(s) that would exclude them from this study. The participant must not have any of the following neurological conditions based on self report (were told by a physician):

• Alzheimer's disease, or any other form of dementia such as Pick's disease, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, significant cognitive and motor impairment from a stroke or corticobasal degeneration;

• Huntington's disease, epilepsy, Parkinson's disease, brain tumor, multiple sclerosis, manic-depressive disorder, or schizophrenia;

• The participant must not have had a head injury with prolonged loss of consciousness (over 30 minutes) within the past five years;

• The participant must not have a current alcohol or substance abuse diagnosis, or must have been treatment free for the past 24 months;

• The participant must not have had a diagnosis of depression or anxiety disorder in the past 4 months and must not currently be under treatment for depression or anxiety disorder. [A participant who was previously diagnosed with depression or anxiety disorder but completed treatment more than four months ago is eligible.];

• The participant must not currently use of any of the following medications: Aricept, Cognex, Exelon, Reminyl, or Hydergine;

• The participant must not have blindness, deafness, language difficulties or any other disability that may prevent completion of the memory screen.